Company Profile

Thelium Therapeutics Inc
Profile last edited on: 9/13/2022      CAGE: 89KV5      UEI: RQA9J88QTJG4

Business Identifier: Developing agents to restore intestinal barriers in inflammatory diseases
Year Founded
2019
First Award
2019
Latest Award
2022
Program Status
Active
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

220 EAST 70TH STREET 9C
New York, NY 10021
   (312) 752-7742
   info@theliumtx.com
   www.theliumtx.com
Location: Single
Congr. District: 12
County: New York

Public Profile

An early-stage preclinical company developing agents designed to restore intestinal barriers in inflammatory diseases, Thelium Therapeutics is a pharmaceutical company structured around development of therapeutics to restore barrier homeosasis in epithelium and endothelium.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2022 2 NIH $1,019,309
Project Title: A Novel Approach to Restore Epithelial Barrier Homeostasis to Treat Inflammatory Bowel Disease

Key People / Management

  Miro Brajenovic -- Chief Executive Officer

  Vallen Graham -- Co-founder, Head of Research

  W Vallen Graham -- Co-founder, Head of Research

  Petr Jansa -- Head of Medicinal Chemistry

  Nargis Kohgadai -- Associate Scientist

  Roman Sakowicz -- Chief Technology Officer, Head of Discovery

  Naomi Vinod -- Research Associate intern

Company News

There are no news available.